Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

If It Ain’t Broke…: FDA Committee Supports Retaining Soliris REMS

This article was originally published in RPM Report

Executive Summary

FDA’s annual REMS reviews haven’t been the most dramatic advisory committees in recent years. The latest review is the first to involve a major commercial product – Alexion’s Soliris – but also looked at a program that appears successful and non-controversial.

You may also be interested in...



When To End A REMS? Soliris Review Stirs Debate On How To Scale Back

Risk management program for Alexion’s orphan drug eculizumab appears to be succeeding, but what does FDA need to see to make it less burdensome?

The End of the REMS Era? Entyvio Approval Is Another Marker

FDA approved Takeda’s UC and Crohn’s disease therapy without a REMS – even though the product has a theoretical risk of causing PML, based on its similarity to Biogen’s Tysabri.

Class-Wide REMS: "A Self-Propagating Purgatory"

It hasn't been easy for two dozen companies to work together in trying to craft a viable class-wide risk management program for long-acting opioids. If they are successful, expect FDA to push for more class-wide REMS.

Topics

Related Companies

UsernamePublicRestriction

Register

PS079764

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel